Newsletter | July 27, 2022

07.27.22 -- Improve Solubility And Spray Drying Throughput For Brick Dust Compounds

 
Enabling Technologies To Reduce Solvent Consumption, Cycle Times, And Costs
 

Spray drying is commonly used to increase bioavailability, but these brick dust compounds require additional innovative steps if spray drying is to yield a commercially attractive process. This webinar reviews three technologies that increase organic solvent solubility, how to implement them in spray-drying processes, and the advantages and risks of each technology.

Advanced Technologies To Improve Spray-Drying Throughput
 

Poorly water-soluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render a drug ineffective in patients. This paper presents three approaches to overcome poor solubility in organic solvents for spray drying as well as case studies outlining their successful application during development.

A Q&A: New Technologies To Improve Solubility Of Brick Dust Compounds
 

David Lyon, Ph.D., senior fellow, and Molly Adam, R&D spray drying expert, bioavailability enhancement, answer questions about three enabling technologies designed to improve drug solubility in organic solvents for spray drying as well as case studies detailing the process for each one.

Spray-Dried Dispersions Enable Local Delivery For Lung Cancer
 

Spray drying is a useful particle engineering technique that can deliver the particles within the necessary specifications and can therefore be used to manufacture dry powder inhaler treatments. Two case studies detailing the success of spray drying serve as a critical tool in developing innovative and effective cancer therapies.

Spray-Dried Bevacizumab: Treating Non-Small Cell Lung Cancer
 

Development of physically stable, biologically active dry powder formulations of large molecules for inhalation has remained a challenge. Here, spray drying was used to manufacture a dry powder pulmonary formulation of bevacizumab, a monoclonal antibody approved to treat non-small cell lung cancer (NSCLC) by intravenous infusion.